Since basal activity of PARP1 is critically important in controlling gene transcription and maintaining genomic stability, prolonged exposure to PARP inhibitors could pose potential adverse effects when applied for neurodegenerative diseases that require long treatment plans. The gene discussed is PARP1; the disease is neurodegenerative disease.